PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19268584-3	2009	By virtue of the installation of alternative halogenated piperidinyl benzimidazolone privileged structures, in combination with a key (S)-methyl group, novel PLD inhibitors with low nM potency and unprecedented levels of PLD1 isoform selectivity (approximately 1700-fold) over PLD2 were developed.	piperidinyl benzimidazolone	57-84	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	158-161
25466173-1	2014	This Letter describes the on-going SAR efforts based on two scaffolds, a PLD1-biased piperidinyl benzimidazolone and a PLD2-biased piperidinyl triazaspirone, with the goal of enhancing PLD inhibitory potency and isoform selectivity.	piperidinyl benzimidazolone	85-112	phospholipase D1	Homo sapiens	73-77
25466173-1	2014	This Letter describes the on-going SAR efforts based on two scaffolds, a PLD1-biased piperidinyl benzimidazolone and a PLD2-biased piperidinyl triazaspirone, with the goal of enhancing PLD inhibitory potency and isoform selectivity.	piperidinyl benzimidazolone	85-112	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	73-76
19268584-3	2009	By virtue of the installation of alternative halogenated piperidinyl benzimidazolone privileged structures, in combination with a key (S)-methyl group, novel PLD inhibitors with low nM potency and unprecedented levels of PLD1 isoform selectivity (approximately 1700-fold) over PLD2 were developed.	piperidinyl benzimidazolone	57-84	phospholipase D1	Homo sapiens	221-225